Institute of Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Center for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle, Germany.
School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
PLoS One. 2022 Oct 6;17(10):e0275171. doi: 10.1371/journal.pone.0275171. eCollection 2022.
Breast cancer is the leading cancer among women with an annual crude incidence of 27.4 per 100,000 in Ethiopia. The aims of this study were to (a) estimate the unit cost of breast cancer treatment for the standard Ethiopian patient, (b) identify the cost drivers, (c) project the total cost of breast cancer treatment for the next five years, and (d) estimate the economic burden of the disease in the main specialized tertiary hospital-Tikur Anbessa Specialized Hospital (TASH) Addis Ababa.
Primary data were collected from health and non-health professionals. Secondary data were collected from patient`s charts and official reports from various national and international organisations including data from TASH. To establish work-time estimates, we asked professionals on their time usage.
A total of US$ 33,261 was incurred to treat 52 Addis Ababa resident female breast cancer patients in TASH between July 2017 and June 2019. The unit cost of treatment for a hypothetical breast cancer patient to complete her treatment was US$ 536 for stage I and US$ 705 for stage II and III using the existing infrastructure. This cost increased to US$ 955 for stage I and US$ 1157 for stage II and III when infrastructure amortization was considered. The projected total costs of breast cancer treatment in TASH is between US$ 540,000 and US$ 1.48million. However, this will increase to US$ 870,000 and US$ 2.29 million when the existing fixed assets are changed.
The economic burden of breast cancer treatment is high compared to the economic status of the country. Thus, it is recommended that TASH should revise its charges and breast cancer should be included in the Social and Community based health insurance scheme. JEL classification: H51, H75, I18, P46.
乳腺癌是女性中发病率最高的癌症，在埃塞俄比亚，每年的粗发病率为每 10 万人 27.4 例。本研究的目的是：(a) 估算标准埃塞俄比亚患者乳腺癌治疗的单位成本；(b) 确定成本驱动因素；(c) 预测未来五年乳腺癌治疗的总成本；(d) 估计主要专科医院——提克塞尔安贝萨专科医院（TASH）在埃塞俄比亚的疾病经济负担。
从卫生和非卫生专业人员那里收集原始数据。从患者病历和来自不同国家和国际组织的官方报告中收集二手数据，包括 TASH 的数据。为了确定工作时间估计，我们询问了专业人员的时间使用情况。
2017 年 7 月至 2019 年 6 月期间，TASH 共治疗了 52 名来自亚的斯亚贝巴的女性乳腺癌患者，总费用为 33261 美元。使用现有基础设施，假设一名乳腺癌患者完成治疗的单位治疗成本为 I 期 536 美元，II 期和 III 期 705 美元。当考虑基础设施摊销时，I 期和 II 期和 III 期的成本分别增加到 955 美元和 1157 美元。TASH 乳腺癌治疗的预计总成本在 54 万美元至 148 万美元之间。但是，如果现有的固定资产发生变化，这一数字将增加到 87 万美元和 229 万美元。
与国家经济状况相比，乳腺癌治疗的经济负担很高。因此，建议 TASH 应调整其收费标准，并将乳腺癌纳入社会和社区医疗保险计划。JEL 分类：H51、H75、I18、P46。
